Intech Investment Management LLC Purchases 20,795 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Intech Investment Management LLC boosted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 121.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,902 shares of the company's stock after buying an additional 20,795 shares during the period. Intech Investment Management LLC owned approximately 0.05% of Akero Therapeutics worth $1,054,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of AKRO. Summit Financial Wealth Advisors LLC bought a new position in shares of Akero Therapeutics in the third quarter worth $205,000. Victory Capital Management Inc. purchased a new stake in Akero Therapeutics during the 3rd quarter worth about $211,000. AlphaQuest LLC boosted its stake in Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after purchasing an additional 8,147 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Akero Therapeutics during the 3rd quarter valued at about $265,000. Finally, XTX Topco Ltd bought a new stake in shares of Akero Therapeutics during the third quarter valued at about $308,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. HC Wainwright raised their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. UBS Group boosted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Finally, Citigroup upped their target price on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $76.29.

Remove Ads

Insider Buying and Selling at Akero Therapeutics

In other news, COO Jonathan Young sold 10,000 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the completion of the sale, the chief operating officer now owns 218,083 shares of the company's stock, valued at approximately $6,112,866.49. This represents a 4.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Patrick Lamy sold 5,000 shares of Akero Therapeutics stock in a transaction on Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the transaction, the vice president now owns 33,492 shares in the company, valued at approximately $1,910,048.76. The trade was a 12.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 252,135 shares of company stock worth $12,345,079 over the last ninety days. Insiders own 7.94% of the company's stock.

Akero Therapeutics Price Performance

NASDAQ AKRO traded up $0.16 during trading hours on Tuesday, reaching $45.24. 874,613 shares of the stock traded hands, compared to its average volume of 807,909. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock has a 50 day simple moving average of $44.85 and a two-hundred day simple moving average of $34.78. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The company has a market cap of $3.60 billion, a price-to-earnings ratio of -12.06 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.